Targeting apolipoprotein C-III: a game changer for pancreatitis prevention in severe hypertriglyceridemia.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2025-06-01 Epub Date: 2025-02-27 DOI:10.1097/MED.0000000000000906

Bram M Weijs, Reindert F Oostveen, Jordan M Kraaijenhof, Erik S G Stroes

{"title":"Targeting apolipoprotein C-III: a game changer for pancreatitis prevention in severe hypertriglyceridemia.","authors":"Bram M Weijs, Reindert F Oostveen, Jordan M Kraaijenhof, Erik S G Stroes","doi":"10.1097/MED.0000000000000906","DOIUrl":null,"url":null,"abstract":"Purpose of review: The aim of this review is to examine recent advancements in RNA-targeted therapies for the management of severe hypertriglyceridemia (sHTG) and prevention of sHTG-associated acute pancreatitis.Recent findings: Recent developments in RNA-targeted therapies, aimed at inhibiting apolipoprotein C-III (apoC-III), have demonstrated substantial and sustained reductions in triglyceride levels. Novel therapies, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), such as volanesorsen, olezarsen, and plozasiran, have shown promising results in recent trials. These therapies not only effectively lower plasma triglyceride levels but also significantly reduce the incidence of acute pancreatitis.Summary: SHTG is a high-burden metabolic disorder that is associated with a significantly increased incidence and severity of acute pancreatitis. Traditional lifestyle interventions and conventional therapies, including fibrates and n-3 fatty acids, often provide only modest reductions in triglycerides and fail to prevent sHTG-associated acute pancreatitis. The emergence of novel and targeted RNA-therapies represents a potential breakthrough in the management of sHTG and acute pancreatitis prevention.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"126-132"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Endocrinology & Diabetes and Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MED.0000000000000906","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The aim of this review is to examine recent advancements in RNA-targeted therapies for the management of severe hypertriglyceridemia (sHTG) and prevention of sHTG-associated acute pancreatitis.

Recent findings: Recent developments in RNA-targeted therapies, aimed at inhibiting apolipoprotein C-III (apoC-III), have demonstrated substantial and sustained reductions in triglyceride levels. Novel therapies, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), such as volanesorsen, olezarsen, and plozasiran, have shown promising results in recent trials. These therapies not only effectively lower plasma triglyceride levels but also significantly reduce the incidence of acute pancreatitis.

Summary: SHTG is a high-burden metabolic disorder that is associated with a significantly increased incidence and severity of acute pancreatitis. Traditional lifestyle interventions and conventional therapies, including fibrates and n-3 fatty acids, often provide only modest reductions in triglycerides and fail to prevent sHTG-associated acute pancreatitis. The emergence of novel and targeted RNA-therapies represents a potential breakthrough in the management of sHTG and acute pancreatitis prevention.

查看原文本刊更多论文

靶向载脂蛋白 C-III：改变严重高甘油三酯血症患者胰腺炎预防的游戏规则。

综述目的：本综述的目的是研究rna靶向治疗严重高甘油三酯血症（sHTG）和预防sHTG相关急性胰腺炎的最新进展。最近的发现：rna靶向治疗的最新进展，旨在抑制载脂蛋白C-III (apoC-III)，已经证明了甘油三酯水平的显著和持续降低。新疗法，包括反义寡核苷酸（ASOs）和小干扰RNA (siRNA)，如volanesorsen， olezarsen和plzasiran，在最近的试验中显示出有希望的结果。这些疗法不仅有效降低血浆甘油三酯水平，而且显著降低急性胰腺炎的发生率。SHTG是一种高负担代谢紊乱，与急性胰腺炎的发生率和严重程度显著增加相关。传统的生活方式干预和常规治疗，包括贝特酸盐和n-3脂肪酸，通常只能适度降低甘油三酯，不能预防shtg相关的急性胰腺炎。新的靶向rna疗法的出现代表了sHTG管理和急性胰腺炎预防的潜在突破。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Endocrinology & Diabetes and Obesity ENDOCRINOLOGY & METABOLISM-

CiteScore

5.80

自引率

3.10%

发文量

128

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Endocrinology, Diabetes and Obesity delivers a broad-based perspective on the most recent and exciting developments in the field from across the world. Published bimonthly and featuring twelve key topics – including androgens, gastrointestinal hormones, diabetes and the endocrine pancreas, and neuroendocrinology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.